For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Semaglutide

Also known as: Semaglutide (GLP-1 agonist)

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Where to buy · live market data

Who's worth your money for Semaglutide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (95) of 7 scored sellers

$4.67/mg

$70.00 · 15mg · 99.2% purity

Best value

Lowest $/mg among scored sellers

$1.00/mg

$10.00 · 10mg

no COAs yet

Most tested

11 independent COAs on file

$9.00/mg

$90.00 · 10mg · 99.9% purity

Average price

$9.02/mg

Sellers

63

45-day trend

+12.6%

55 of 63 sellers have a current price· 48 stale hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Semaglutide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Semaglutide

CAS

910463-68-2

Molecular formula

C187H291N45O59

Typical dose range

0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks

Half-life

~7 days

Independent evidence

COAs for Semaglutide

185 third-party tests across 28 vendors. Each card links to the full report.

All 185 COAs for Semaglutide →
Measured purity 99.0%–100.0% across 113 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.85 %
Aug 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Peptide Plugs· batch 189-02-DK

Aggregated · 3rd-party listing
99.76 %
Jul 2026
ILS Labs Strong

For

Semaglutide

by Hydro Research Peptides· batch HR-2026-7341

Aggregated · 3rd-party listing
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Semaglutide

by Longeva· batch B-2026-SEMA-5-001

✓ Vendor-published
99.94 %
Jun 2026
TrustPointe Analytics Moderate

For

Semaglutide

by Peptide Partners· batch SPL-4149

COA on file
Aggregated · 3rd-party listing
99.07 %
Jun 2026
ILS Labs Strong

For

Semaglutide

by Peptide Plugs· batch 125-01-SM

Aggregated · 3rd-party listing
99.90 %
Jun 2026
Prime Analytical Laboratories, LLC

For

Semaglutide

by Soma Peptides· batch SEV052657

Aggregated · 3rd-party listing
99.75 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

✓ Vendor-published
99.63 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

COA on file
Aggregated · 3rd-party listing
99.91 %
May 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Blank Peptides· batch GS10-052026-4

Aggregated · 3rd-party listing
99.23 %
May 2026
Horizon Analytical

For

Semaglutide

by Pepsgpt· batch P-2885342-P

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3022026SM

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3142026SM

Aggregated · 3rd-party listing
99.17 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2242026SM

✓ Vendor-published
99.96 %
Apr 2026
Kovera Labs

For

ION-1S

by Ion Peptide· batch ION1S20-04172026

COA on file
Aggregated · 3rd-party listing
99.70 %
Apr 2026
BTLabs Moderate

For

Semaglutide

by Vertex Labs· batch SM0000038

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Semaglutide

by OROS Research· batch OR-LPGLPS10-426-B3

Aggregated · 3rd-party listing
99.68 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3272026SM

Aggregated · 3rd-party listing
99.63 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3222026SX

Aggregated · 3rd-party listing
99.80 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

Semaglutide

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.41 %
Mar 2026
AccumarkLabs Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2182026SM

Aggregated · 3rd-party listing
99.02 %
Mar 2026
Vanguard Laboratory Strong · HPLC

For

Semaglutide

by Prime Peptides· batch 2122026SM

Aggregated · 3rd-party listing
99.83 %
Mar 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Orbitrex Peptides· batch 1G200426

Aggregated · 3rd-party listing
99.45 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Qihang Peptide· batch 3

Aggregated · 3rd-party listing
99.67 %
Feb 2026
Janoshik Analytical Limited

For

Semaglutide

by Peptide Crafters· batch PC-G2-S10

Research depth

23 citations indexed for Semaglutide

All research on Semaglutide →

meta-analysis · 2026

Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent.

animal · 2026

Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice

Obesity is a major contributor to cardiometabolic disease, and pharmacological therapies, such as semaglutide, are increasingly used to induce weight loss.

review · 2026

Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis

Background/objectives Obesity is a chronic, relapsing disease associated with multiple serious comorbidities. Semaglutide has emerged as an effective pharmacological option for obesity management, owing to its substantial effects on weight loss, cardiometabolic risk factors, and patient-reported outcomes.

cohort · 2026

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Introduction Glucagon-like peptide-1 receptor agonists are effective glucose-lowering agents with established benefits on body weight and cardiometabolic outcomes.

Study · 2026

Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial

Background This subgroup analysis assessed the efficacy and safety of semaglutide in the Japanese subgroup versus the overall trial population of ESSENCE (part 1) and evaluated the impact of baseline characteristics.

Study · 2026

Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study

Background Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity.